Cardiometabolic & kidneyCohort study
Large-scale AI analysis reveals missed opportunities in albuminuria testing and disease-modifying therapy implementation
- retrospective cohort study
- tertiary referral centre
- AI-driven data extraction (CTcue)
- weighted logistic regression model
Authors' conclusion
Albuminuria is substantially underdetected in cardiology practice, possibly contributing to underuse of effective CKM therapies. Systematic UACR screening with structured treatment protocols may help close this gap and improve outcomes for patients with CKM disease.
Study context
- Population
- All adults seen at the cardiology department of a tertiary referral centre between 2019 and 202444.8% female, mean age 64.4 years
- Participants
- 77,351 participants
- Exposure
- patients with documented vs. predicted albuminuria
Main finding
As reported in the abstract
Patients with a recorded urine albumin-to-creatinine ratio (UACR)
8.9%
Albuminuria among those with a recorded UACR
46.4%
Observational data: associations, not effects.
Further findings
Use of disease-modifying therapies
renin-angiotensin system inhibitors
SGLT2 inhibitors
finerenone documented albuminuria <1% · predicted albuminuria <1%
UACR testing rates in high-risk groups
- diabetes
- 29.9%
- heart failure
- 21.7%
- hypertension
- 13.7%
Predicted prevalence of albuminuria in untested patients
- All untested patients
- 36.6%
- eGFR <30 mL/min/1.73m2
- 70.0%
- heart failure
- 47.8%
- diabetes
- 46.8%
Original publication
Summarised from the published abstract; every number is checked against it